Drug Trial Radar · NCT07899047
Albumin-Bound Paclitaxel (Ⅱ) in Patients With Advanced Breast Cancer
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,372
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
May 2030
Study completion May 2030
Sponsor
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 27, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, prospective, observational real-world study. The study aims to evaluate the efficacy, safety and economic benefits of albumin-bound paclitaxel (Ⅱ) compared with conventional albumin-bound paclitaxel, in patients with HER2-negative advanced breast cancer.
Conditions
- Breast Cancer
- HER2-negative Breast Cancer
- Advanced Breast Cancer
Interventions
Experimental GroupDrug
Regimens containing paclitaxel for injection (albumin bound) (Ⅱ)
control groupDrug
Regimens containing paclitaxel for injection (albumin bound)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: 42 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.